FY2025 Q2 Financial Results Presentation

from the beginning

FY2025 Q2 Financial Results Presentation

Forward-Looking Statements

1. FY2025 Q2 Financial Results

Overview of FY2025 Q2 Results

Revenue

Core Operating Profit

Profit Attributable to Owners of the Company

2. FY2025 Forecast

Revision to the forecast

3. Business Update

Performance

Performance

4. R&D Update

5DXd ADCs Update

Advancing ENHERTU into Early HER2+ Breast Cancer

Advancing ENHERTU into Early HER2+ Breast Cancer

Regulatory Updates

Paving the way for the new 1L SOC in mTNBC

Combination of DATROWAY + Durvalumab in TNBC

New Study to Address an Unmet Need in UC

Striving to Fill the Unmet Need in SCLC

Striving to Fill the Unmet Need in SCLC

Confirmed Clinical Meaningful Responses in Ph2 Part

Other Clinical and Regulatory Approval Status Updates

Next Wave Update

Initial Results from a FIH Study Dose Escalation Part

CD37-directed ADC for Hematological Malignancies

New Program for Solid Tumors including CRPC

New Program for Solid Tumors

News Flow

FY2025 News Flow

Upcoming IR Events

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7

• Q&A 8

• Q&A 9

• Q&A 10

• Q&A 11